Topadur Pharma

Zurich-Schlieren, Switzerland, 7 September 2023

We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.

This achievement is a demonstration to our team's dedication and our partners' support.

We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.

Please check out the link below.

‍

7.4.22

Press Release

TOPADUR in collaboration with USZ / UZH was awarded CHF 605k by Innosuisse

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.

7.9.23

News

We are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.

27.6.22

News

A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.